«MYELOFIBROSES» İLE İLİŞKİLİ İNGILIZCE KİTAPLAR
myelofibroses sözcüğünün kullanımını aşağıdaki kaynakça seçkisinde keşfedin.
myelofibroses ile ilişkili kitaplar ve İngilizce edebiyattaki kullanımı ile ilgili bağlam sağlaması için küçük metinler.
1
Morphologie Et Embryologie: Morphology and Embryology
But there are also the so-called either acute or subacute myelofibroses,
malignant myelofibroses with short evolution (between 5— 14 months in our
personal observations), with pancytopenia where fibrosis appears quickly (Fig. 3
C). In these ...
2
Modern Trends in Human Leukemia III: Newest Results in ...
The Philadelphia-chromosome in chronic granulocytic leukemia (CGL) compared
with chronic megakaryocyte granulocytic myelosis (CMGM). primary
myelofibroses, and polycythemia vera in a total of 74 patients significantly higher
than in ...
Rolf Neth, R. C. Gallo, P. -h. Hofschneider, 1979
3
Death Receptors in Cancer Therapy
... 8 essential thrombocythemias, 6 acute lymphocytic leukemias, 6 acute
myeloblastic leukemias, 3 hairy-cell leukemias, 3 Burkitt's lymphomas, 3
polycythemia veras, 2 myelofibroses, and 2 chronic myelomonocytic leukemias),
but could not ...
Myelofibroses are a very heterogeneous group of diseases that may be caused
by myeloproliferative disorders or by therapy for leukemia or lymphoma. They
result from fibroblast proliferation within the bone marrow and may be associated
...
Ernst Rummeny, Peter Reimer, 2011
5
Hematology: Basic Principles and Practice
Ianotto JC, Kiladjian JJ, Demory JL, et al: PEG—IFN—alpha—2a therapy in
patients with myelofibrosis: A study of the French Groupe d'Etudes des
Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (
FIM).
Ronald Hoffman, Edward J. Benz, Jr., Leslie E. Silberstein, 2013
6
Biotechnology and Biopharmaceuticals: Transforming Proteins ...
“PEG-lFN-alpha-2a therapy in patients with myelofibrosis: a study of the French
Groupe d'Etudes des Myelofibroses (GEM) and France lntergroupe des
syndromes Myeloproliferatifs (FIM)." Br J Haematol 146(2): 223—5. lsaacs, A.
and J.
7
Wintrobe's Clinical Hematology
PEGIFNalpha2a therapy inpatientswith myelofibrosis: astudy of theFrench
Groupe d'Etudesdes Myelofibroses (GEM)andFrance Intergroupe dessyndromes
Myeloproliferatifs (FIM).BrJ Haematol 2009;146:223–225. 100. Harrison C,
Kiladjian ...
John P. Greer, Daniel A. Arber, Bertil Glader, 2013
8
Hematology: Diagnosis and Treatment
Ianotto JC, Kiladjian JJ, Demory JL, et al: PEG—IFN—alpha—2a therapy in
patients with myelofibrosis: A study of the French Groupe d'Etudes des
Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (
FIM).
Ronald Hoffman, Edward J. Benz Jr., Leslie E. Silberstein, 2013
... MYELOCYSTOMATOSES MYELOCYSTOMATOSIS
MYELOCYSTOMENINGOCELE MYELOCYTE MYELOCYTES MYELOCYTIC
MYELOENCEPHALITIDES MYELOENCEPHALITIS MYELOFIBROSES
MYELOFIBROSIS MYELOFIBROTIC ...
Maliha Mendoza Mahmood, 2013
10
Myeloproliferative Neoplasms: Biology and Therapy
PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French
Groupe d'Etudes des Myelofibroses (GEM) and France intergroupe des
syndromes Myéloprolifératifs (FIM). Br J Haematol. 2009;146:223–225. 35.
Buxhofer-Ausch ...
Srdan Verstovsek, Ayalew Tefferi, 2010
«MYELOFIBROSES» TERİMİNİ İÇEREN HABERLER
Ulusal ve uluslararası basında konuşulanları ve
myelofibroses teriminin aşağıdaki haberlerde hangi bağlamda kullanıldığını keşfedin.
Revisiting the Role of Interferon Alfa-2 in the Treatment of Early …
PEG-INF-2a therapy in patients with myelofibrosis. A study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe ... «Cancer Network, Ağu 11»
